Reneo Pharmaceuticals, Inc. (RPHM) Financial Statements (2024 and earlier)

Company Profile

Business Address 18575 JAMBOREE ROAD
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments101,173,000147,670,000
Cash and cash equivalents19,927,000124,660,000
Short-term investments81,246,00023,010,000
Other undisclosed current assets5,180,0006,064,000
Total current assets:106,353,000153,734,000
Noncurrent Assets
Operating lease, right-of-use asset1,292,000 
Property, plant and equipment453,000212,000
Other noncurrent assets84,00078,000
Total noncurrent assets:1,829,000290,000
TOTAL ASSETS:108,182,000154,024,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,720,0006,202,000
Accounts payable1,893,0002,022,000
Accrued liabilities4,827,0004,180,000
Other undisclosed current liabilities404,000 
Total current liabilities:7,124,0006,202,000
Noncurrent Liabilities
Liabilities, other than long-term debt1,088,000611,000
Deferred compensation liability, classified29,000444,000
Deferred rent credit  167,000
Operating lease, liability1,059,000 
Total noncurrent liabilities:1,088,000611,000
Total liabilities:8,212,0006,813,000
Equity
Equity, attributable to parent99,970,000147,211,000
Common stock3,0003,000
Additional paid in capital236,693,000231,902,000
Accumulated other comprehensive income (loss)(43,000)34,000
Accumulated deficit(136,683,000)(84,728,000)
Total equity:99,970,000147,211,000
TOTAL LIABILITIES AND EQUITY:108,182,000154,024,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(53,848,000)(39,818,000)
Operating loss:(53,848,000)(39,818,000)
Nonoperating income (expense)1,893,000(252,000)
Loss, foreign currency transaction, before tax  (300,000)
Other nonoperating income1,893,00048,000
Loss from continuing operations before equity method investments, income taxes:(51,955,000)(40,070,000)
Other undisclosed income from continuing operations before income taxes  300,000
Loss from continuing operations:(51,955,000)(39,770,000)
Loss before gain (loss) on sale of properties:(39,770,000)
Net loss available to common stockholders, diluted:(51,955,000)(39,770,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(51,955,000)(39,770,000)
Other comprehensive income (loss)(77,000)34,000
Other undisclosed comprehensive loss  
Comprehensive loss:(52,032,000)(39,736,000)
Other undisclosed comprehensive income, net of tax, attributable to parent  
Comprehensive loss, net of tax, attributable to parent:(52,032,000)(39,736,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: